prophecy trial: ar-v7 ctcs as a biomarker in mcrpc
Published 6 years ago • 114 plays • Length 3:33Download video MP4
Download video MP3
Similar videos
-
4:21
case 3: clinical relevance of the ar-v7 biomarker in mcrpc
-
2:34
ar-v7 as a biomarker in crpc
-
1:25
potential of ctcs for biomarker detection in prostate cancer
-
3:56
ctc enumeration as a prognostic biomarker in prostate cancer
-
1:00
dr. armstrong on the utility of ar-v7 as a biomarker in prostate cancer
-
5:08
axumin vs pylarify psma pet/ct
-
12:58
targeted and systematic prostate biopsy
-
44:55
session 7 - how to use your qa device for psqa
-
8:53
prognostic biomarkers to guide treatment of mcrpc
-
21:52
ar v7 predicts response in crpc
-
1:12
antonarakis: ar-v7, taxane response in mcrpc
-
5:37
ar-v7 testing in mcrpc
-
36:09
ar-v7 as a biomarker to identify adt-resistant patients - emmanuel antonarakis
-
1:04
dr. emmanuel s. antonarakis on the future of the ar-v7 biomarker in prostate cancer
-
6:14
androgen receptor splice variant, ar-v7, as prostate cancer biomarker
-
1:51
tenascin-c activated src regulates ar-v7 related to treatment resistance in prostate cancer
-
0:42
dr. rathkopf on ar-v7 biomarker in prostate cancer
-
1:32
dr. antonarakis discusses ar-v7 and response to taxanes in men with mcrpc
-
6:56
ar-v7 testing for men with advanced stage prostate cancer
-
29:02
ar-v7 in castration resistant prostate cancer
-
5:41
biomarker analysis of olaparib with or without cediranib in mcrpc
-
1:34
an oral ar/ar-v7 protac for the treatment with castration-resistant prostate cancer (crpc)